Public medical-device company (ASX SLD since December 2025), developer of Evoke closed-loop spinal-cord stimulation and EVA sensing/programming for pain. Mike Mathias is current CEO; this is spinal stimulation, not a brain implant.
A$230M 2025-12-05 0 participations $100M 2025-01-17 Redmile Group , Wellington Management , TPG Life Sciences , Fidelity Management & Research Company , Action Potential Venture Capital , T. Rowe Price , Piper Heartland $150M 2023-04-13 Wellington Management , Fidelity Management & Research Company , TPG , Redmile Group , Action Potential Venture Capital , T. Rowe Price $125M 2022-03-02 Redmile Group , Fidelity Management & Research Company , T. Rowe Price
SHOW MORE
team@apexlogos.ai · 19 hours ago
RELATED team@apexlogos.ai · 20 hours ago
BCI research snapshot, reviewed 2026-10-06. Company identity: SaludaMedical. This is the pre-import evidence dossier; historical statements about database absence or review are archival. Unverified claims remain research leads, not validated facts.
Part 1/1
# Saluda Medical
Accessed: 2026-10-06. Research report for human review; no database changes made. Direct image URLs are extracted source assets, not invented filenames. Funding ledger is verified events found, not a complete lifetime total.
## Identity and pasted claims
[Saluda Medical Inc.](https://www.saludamedical.com/ ) is an operating public neuromodulation company, ASX SLD, listed December5 2025. It redomiciled as a Delaware corporation in 2023; Australian origin must not be mistaken for current US legal domicile. Bloomington, Minnesota is current headquarters; Australian office is now Macquarie Park, not historical Artarmon. Company history associates founding with 2013; exact incorporation date remains unverified. [Primary 2023 financing/redomiciliation](https://www.saludamedical.com/press-releases/saluda-medical-announces-150m-equity-financing-led-by-wellington-management-with-fidelity-management-research-company-and-tpg/ ), [current investor site](https://www.saludamedical.com/international/investor-relations/ ).
Pasted Barry Regan CEO is stale. Current official team lists **Mike Mathias** CEO; September7 2026 appointment date appears in [executive’s self-profile](https://www.linkedin.com/in/mike-mathias-59016b8 ) and [secondary report](https://stockwirex.com/asx-stock-news/biotech-health/sld-saluda-medical-ceo-transition-september-2026/ ); exact date should be rechecked against original ASX notice before a date-precise import. Current CEO identity is supported by the official company page. Founder John Parker transitioned to chief scientific officer in 2021 under [official leadership announcement](https://www.saludamedical.com/press-releases/saluda-medical-announces-executive-leadership-changes/ ); do not imply he remains current executive without newer evidence.
Evoke is a real closed-loop spinal-cord stimulation system for pain, not a brain implant. EVA is the sensing/programming technology suite rather than a separate implant. Active status passes but public-company status is missing from paste. The [October6 2026 company product announcement](https://www.newswise.com/articles/saluda-medical-expands-access-to-first-and-only-fda-approved-closed-loop-surgical-paddle-lead-with-full-us-commercial-release-of-cap24 ) concerns CAP24 paddle-lead US commercialization. Pasted USD668M lifetime financing is not supported by a reconciled primary ledger.
## Images and team
Logo: https://www.saludamedical.com/international/wp-content/uploads/2023/02/saluda-medical.png — official page image. Current leadership roles and portrait links extracted through [investor site](https://www.saludamedical.com/international/investor-relations/ ).
| Person | Role / currency | Profile and evidence | Direct pfp URL |
|---|---|---|---|
| Mike Mathias | Current CEO; September2026 appointment | [Official team](https://www.saludamedical.com/international/investor-relations/ ) | https://www.saludamedical.com/international/wp-content/uploads/2025/06/website-elements-2-150x150.png |
| James Erickson | CFO | [Official team](https://www.saludamedical.com/international/investor-relations/ ) | https://www.saludamedical.com/international/wp-content/uploads/2023/12/website-elements-1-150x150.png |
| Kristin Caplice | Chief legal officer | [Official team](https://www.saludamedical.com/international/investor-relations/ ) | https://www.saludamedical.com/international/wp-content/uploads/2023/02/kristin-caplice-1-150x150.jpg |
| Aidan O’Sullivan | COO | [Official team](https://www.saludamedical.com/international/investor-relations/ ) | https://www.saludamedical.com/international/wp-content/uploads/2025/10/website-elements-14-150x150.png |
| David First | Chief people officer | [Official team](https://www.saludamedical.com/international/investor-relations/ ) | https://www.saludamedical.com/international/wp-content/uploads/2024/04/website-elements-4-150x150.png (official team image link) |
| Dean Karantonis | CTO | [Official team](https://www.saludamedical.com/international/investor-relations/ ) | https://www.saludamedical.com/international/wp-content/uploads/2023/02/04_dean_karantonis_321_pp_400-1-150x150.jpg |
| Doug Godshall | Board chair | [Official team](https://www.saludamedical.com/international/investor-relations/ ) | Unavailable from retrieved team assets. |
| Barry Regan | Former CEO (July2025–September2026) | [Official team](https://www.saludamedical.com/international/investor-relations/ ) | Unavailable from current team; superseded CEO portrait not selected. |
John Parker: founder/former CEO; [2021 appointment evidence](https://www.saludamedical.com/press-releases/saluda-medical-announces-executive-leadership-changes/ ); direct pfp unavailable from the consulted founding announcement. Jim Schuermann was president/CEO in 2021–2023 sources, a historical role rather than current CEO.
## Financing ledger
| Announced | Amount | Type | Lead / named investors | Evidence |
|---|---|---|---|---|
| 2022-03-02 | USD125M | Equity | Redmile Group lead; Fidelity Management & Research Company, T. Rowe Price | [Company release](https://www.saludamedical.com/press-releases/saluda-medical-announces-125m-equity-financing-led-by-redmile-group-llc-and-new-investors-fidelity-management-research-company-llc-and-t-rowe-price-associates-inc/ ) |
| 2023-04-13 | USD150M | Equity | Wellington Management lead; Fidelity, TPG, Redmile, Action Potential Venture Capital, T. Rowe Price advised funds/accounts | [Company release](https://www.saludamedical.com/press-releases/saluda-medical-announces-150m-equity-financing-led-by-wellington-management-with-fidelity-management-research-company-and-tpg/ ) |
| 2025-01-17 | USD100M | Equity | Redmile lead; Wellington, TPG Life Sciences, Fidelity, Action Potential Venture Capital, T. Rowe Price, Piper Heartland | [Company release archive](https://www.saludamedical.com/international/press-releases/ ) |
| 2025-12-05 | AUD230.8M (approximately USD150M as issuer reported) | ASX IPO; not a venture round | Primary public offering; do not count AUD and USD as two rounds | [Issuer IPO release](https://www.prnewswire.com/news-releases/saluda-medical-raises-150m-usd-to-fuel-growth-following-asx-ipo-302636136.html ); [quarterly exchange report](https://data-api.marketindex.com.au/api/v1/announcements/XASX%3ASLD%3A2A1649894/pdf/inline/quarterly-activities-appendix-4c-cash-flow-report ) |
No acquisition established. Earlier financing may exist; this partial ledger does not substantiate a lifetime USD668M total. Public market capitalization, sales and research grant funding must not be added to equity rounds.
## Review / import decision
New `SaludaMedical` entity after review; `GoldiSaludaGrade` is unrelated. Import current public status and Mike Mathias; keep Regan, Schuermann and Parker historical. Precise foundation/CEO appointment date and total require follow-up; current official team outranks cached older search excerpts. SHOW MORE